正和药业IPO辅导：74岁实控人姜华持股48%，弟弟、妹妹、儿媳参股

Core Viewpoint - Zhenghe Pharmaceutical Group Co., Ltd. is progressing with its IPO guidance, having initiated the process in July 2017, with the current guidance period extending to the second quarter of 2025 [3] Company Overview - Zhenghe Pharmaceutical was established in June 2002, focusing on the research, production, and sales of traditional Chinese medicine, including pharmaceuticals, health foods, and disinfectants [3] - The company has four wholly-owned subsidiaries: Siping Zhenghe Pharmaceutical Co., Ltd., Tonghua Zhenghe Pharmaceutical Co., Ltd., Jilin Zhenghe Biotechnology Co., Ltd., and Jilin Zhenghe Technology Service Co., Ltd. [3] - Zhenghe Pharmaceutical was listed on the New Third Board in 2015 [3] Product Portfolio - The company holds five exclusive drug varieties in China: Yuanhe Zhengwei Tablets, Compound Ants Active Capsules, Bone-setting Tablets, Cold Detox Tablets, and Strengthening Capsules [3] - It has eight national invention patents, 39 products in the national medical insurance directory, 13 in the national essential drug directory, and 14 in the national low-price drug directory [3] Financial Performance - In 2024, the company reported revenue of 129.42 million, a decrease of 33.66% compared to the previous year [4] - The net profit attributable to shareholders was -9.48 million, a decline of 204.67% year-on-year [4] - The gross profit margin was 41.01%, down from 47.49% in the previous year [4] Shareholding Structure - The largest shareholder, Meihua, holds 48.34% of the shares, followed by Jiang Ke with 6.46% and Mai Su with 6.37% [5] - The shareholding structure indicates a concentration of ownership among a few key individuals [5] Management Team - The management team includes Meng Lingxu as Chairman and General Manager, Jiang Ke as Director and Deputy General Manager, and Diao Renwei as Deputy General Manager and Financial Officer [5] - Relationships among management members suggest a family connection, which may influence company governance [5][6]